Kafalah Program Boosts Saudi SMEs with 17% Growth in Q1 2025
Hamam Hashim, CEO and Board Member of Kafalah, emphasized SMEs as vital drivers of economic growth and income diversification under Saudi Vision 2030. He praised the program's public-private partnerships for empowering SMEs to overcome challenges and expand sustainably. Government and private-sector collaboration, he noted, remains critical to fostering a resilient entrepreneurial ecosystem. Decades of Impact: Kafalah's Legacy Since 2006
Since its 2006 launch, Kafalah has approved over 67,700 guarantees, benefiting more than 25,000 SMEs. Total funding surpassed SAR 115 billion, with guarantees valued at SAR 82 billion. The program continues to reduce lending risks through strategic partnerships, innovative tools, and knowledge-based frameworks.
Kafalah aligns with the National Development Fund's SME Bank to expand financing access. By offering financial guarantees, the program enhances SMEs' eligibility for loans while mitigating risks for lenders. This integrated approach supports Saudi Arabia's goal to cultivate a thriving SME sector, fueling job creation and long-term economic stability.
Short link :
Post Views: 20
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Asharq Al-Awsat
a day ago
- Asharq Al-Awsat
Saudi Industry Ministry: Record 144% Surge in New Mining Exploitation Licenses in H1 2025
The Ministry of Industry and Mineral Resources announced on Thursday a significant rise in new mining exploitation licenses during the first half of 2025, marking a 144% increase compared to the same period in 2024. A total of 22 licenses were issued - up from just nine in the previous year - reflecting growing investor interest and the ministry's efforts to create a more attractive and competitive mining environment. The jump is also aligned with the rapid development of the Saudi mining sector, which is undergoing as part of the country's broader push for economic diversification. According to the ministry's spokesperson, Jarrah bin Mohammed Al-Jarrah, 23 companies were granted exploitation licenses during this period, 16 of them receiving a mining license for the very first time. Combined, these projects represent investments exceeding SAR134 million and cover an area of 47 square kilometers. Annual production capacity from the newly licensed operations is estimated at 7.86 million tons of various mineral resources, including salt, clay, silica sand, low-grade iron ore, feldspar, and gypsum. Currently, the Kingdom holds a total of 239 active mining exploitation and small-mine licenses. Of these, 32 fall under Category A, covering high-value minerals such as gold, copper, phosphate, and bauxite, while the remaining 207 are Category B licenses for a range of other minerals, including silica sand, gypsum, limestone, salt, and clay. The ministry underlined its commitment to advancing the mining sector as a central pillar of Saudi Vision 2030. With mineral wealth in the Kingdom estimated at over SAR9.4 trillion, the sector is being positioned as the third key industrial pillar, supporting national efforts to diversify sources of income and drive sustainable economic growth.
Argaam
a day ago
- Argaam
Ubhar Capital sets SAB rating, TP
Ubhar Capital maintained its "Accumulate" recommendation on Saudi Awwal Bank (SAB), with a target price (TP) of SAR 38.7 per share. The lender's Q2 2025 net profit grew 5% year-on-year (YoY) to SAR 2.1 billion but remained flat sequentially as higher net expected credit loss charges offset gains in operating income. "Provisions rose sharply to SAR 0.2 billion in Q2 2025, up 92% YoY and 52% QoQ, primarily due to higher impairment charges on loans," the brokerage said.
Argaam
2 days ago
- Argaam
Jamjoom Pharma ups profit margin forecast to 33%: CEO
Tarek Youssef Hosny, CEO of Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma), said he expects the company to continue growth and achieve added value, saying that the forecast for the EBITDA margin for 2025 was raised to a range between 31.5-33%, from previous estimates of 30-31.5%, following the company's performance in the first half of the year. In an interview with Argaam, the top executive said that Jamjoom Pharma maintained its exceptional performance during H1 2025, attributing the continued growth to the strong momentum achieved in the first quarter, reflecting the resilience of its strategy in a dynamic operating environment, by focusing on strategic brands, improved operational efficiency, and disciplined cost management. He indicated that enhanced operational efficiency in research and development, manufacturing, and distribution contributed to boost profitability while maintaining a commitment to innovation and quality, adding that the company also continued to strengthen its key partnerships, launch new products, and continue its sustainability efforts. Meanwhile, the company's sales witnessed strong momentum across key markets during H1 2025. The Saudi market continued to drive growth, with revenues rising by 20.6% to SAR 577.8 million, accounting for more than two-thirds of the company's total revenue. Gulf markets accounted for SAR 107.7 million, led by the UAE and Oman, while sales in the Iraqi market grew by 27.3% to SAR 83.2 million, according to the top executive. He also highlighted that revenue from the Egyptian market grew by 12.8% in Egyptian pound, but declined when converted to Saudi riyals due to the depreciation of the Egyptian pound. Meanwhile, revenue from other export markets amounted to SAR 48.4 million, down 10% due to regional tensions in Jordan and Lebanon. However, export growth in Morocco and Libya helped mitigate the negative impact. Hosny also stated that the company is currently re-evaluating its distribution channels to ensure margin sustainability and achieve lower-risk growth in those markets. The company's H1 revenue was backed by several therapeutic areas, most notably general medicine, which grew by 37.7%. The ophthalmology and dermatology segments together accounted for 43.1% of topline. The diabetes drug portfolio grew by 71.5%, while cardiovascular treatments saw a 31.1% increase in sales, he added. Total production at the company's three plants reached 86 million units during H1, topped by the Jeddah plant with 68 million units at a utilization rate of 90.5%. Production at the Egypt plant grew by 54.1%, reaching 14 million units. The new sterile products plant in Jeddah continued its expansion, doubling its annual output to 4 million units with a utilization rate of 32.2%, which supported supplies in ophthalmology and sterile product segments, according to the CEO. As regards the Algeria project, Hosny said the project contributed SAR 6.5 million to H1 profit, as part of the company's expansion strategy in North Africa, while leveraging local manufacturing to enhance efficiency and reduce costs. He noted that this provides a solid platform for future expansion into neighboring North and West African markets. He also highlighted that the company will continue expanding into high-value therapeutic areas, accelerating regional expansion initiatives, and strategically investing in research and development and business alliances, especially in its core focus areas, with disciplined spending and a scalable platform.
